fda drug safety communication naion semaglutide 2025 linked to increased risk of vision loss in diabetes patients Nutritional priorities to support GLP-1

Common Side Effects: Many individuals may experience gastrointestinal side effects, especially when first starting or increasing the dosage

Semaglutide works by activating GLP-1 receptors in the brain to regulate appetite and blood sugar, creating conditions where meaningful weight loss becomes achievable for most patients

Microdosing continues to be studied as a potential avenue to help with side effects and tolerance issues

One of the innovative options we offer is compounded Semaglutide GLP-1, a customized formulation of the medication Semaglutide GLP-1, which has shown promising results in weight loss management

The FDA has approved these medications for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia